FDA Approves First Once-Weekly Basal Insulin, Ending Daily Injections for Millions of Diabetes Patients

For an adult managing type 2 diabetes with daily basal insulin, a single year requires 365 injections. That arithmetic is about to change to 52. The U.S. Food and Drug Administration has approved Awiqli (insulin icodec-abae), the first once-weekly basal insulin, marking the most significant shift in insulin delivery in over two decades.[1][2]

To understand the practical impact of this approval, it helps to distinguish between the types of insulin patients use. Basal insulin is the steady, background insulin that keeps blood sugar stable between meals and overnight. It is entirely separate from the rapid-acting insulin that some patients must take right before eating to cover a specific meal.[2]

Until now, basal insulin has required a daily subcutaneous injection. While highly effective, the daily routine can cause treatment fatigue. Patients may miss doses due to travel, shifting work schedules, or simply the psychological friction of a daily needle. Awiqli, developed by Novo Nordisk, condenses that background coverage into a single weekly dose.[1]

The mechanism that makes a seven-day insulin possible without causing an immediate, dangerous drop in blood sugar relies on a clever piece of molecular engineering. Insulin icodec is designed to bind reversibly to albumin, a protein that is naturally abundant in human blood.[2][3]

Once injected, the insulin molecules attach themselves to the circulating albumin, effectively creating an inactive, slow-release reservoir inside the bloodstream. Over the course of the week, the insulin slowly detaches from the albumin at a steady rate, providing a flat, consistent glucose-lowering effect without dramatic peaks or valleys.[2][3]

The FDA's approval rests on the ONWARDS phase 3 clinical program, which tested the weekly injection against standard daily insulins—such as glargine and degludec—in thousands of patients. The trials were designed to see if a weekly shot could match the tight metabolic control of a daily regimen.[2]

The results demonstrated that the weekly injection was non-inferior at reducing HbA1c, the standard measure of long-term blood sugar control. In some patient cohorts, particularly those who had never used insulin before, the weekly option actually provided slightly superior A1C reductions compared to daily shots.[3]

Crucially, continuous glucose monitoring data showed that patients on the weekly injection spent just as much time in their target blood sugar range—defined as 70 to 180 mg/dL—as those taking daily injections. This "time in range" metric is increasingly viewed by endocrinologists as a more accurate reflection of daily metabolic health than A1C alone.[3]

For patients, the translation of this clinical data is highly practical: if you struggle with the daily burden of injections, a weekly routine could make it easier to stay on track. However, the transition requires careful planning. Because the drug takes time to build up its reservoir and takes a full week to clear from the body, patients cannot simply swap a daily shot for a weekly one on their own.[1][2]

The FDA has also drawn a strict boundary regarding who can safely use this new tool. Awiqli is approved exclusively for adults with type 2 diabetes. It is not approved for type 1 diabetes, nor is it approved for pediatric use.[2]

This exclusion stems from safety data in type 1 diabetes trials, where the weekly insulin resulted in a higher rate of severe hypoglycemic (low blood sugar) events compared to daily insulin. Because a weekly dose is committed for seven days and cannot be quickly adjusted or withdrawn once injected, the FDA determined that the risk of prolonged low blood sugar outweighed the convenience for type 1 patients.[2]

If you have type 2 diabetes and are considering the switch, endocrinologists advise that the first few weeks require heightened vigilance. As the weekly insulin reaches a steady state in your bloodstream, you will need to monitor your glucose levels closely to catch any unexpected drops, as managing hypoglycemia with a long-acting drug requires sustained attention.[2]

While Novo Nordisk is the first to bring a weekly basal insulin to the U.S. market, the landscape is expanding rapidly. Eli Lilly is close behind with its own weekly insulin, efsitora alfa, which recently posted positive Phase 3 results showing comparable efficacy to daily basal insulins.[4][5]

Ultimately, the arrival of weekly basal insulins represents a shift toward human-centric medical design. By reducing the physical and mental friction of chronic disease management, these therapies acknowledge that the best medication is the one a patient can actually integrate into their life.[2][3]